Pfizer Inc. (PFE) stock forecast and price target
Price $28.89 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($28.89)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $3.05 | −5.2% | $63.1B |
| Next fiscal year ends December 31, 2027 | $2.95 | −3.4% | $60.8B |
| Next quarter ends December 31, 2026 | $0.69 | +4.6% | $17.2B |
| Quarter after ends March 31, 2027 | $0.70 | −7.0% | $14.1B |
Consensus of the analysts covering Pfizer, updated daily. In the last 30 days 16 estimates were raised and 4 lowered.
Our model vs. Wall Street
Analysts see 4.6% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Pfizer’s intrinsic value about 31% below today’s market value, and it scores 2.2 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Pfizer stock price target?
The average 12-month target from 26 analysts is $30.22, 4.6% above the current price of $28.89 Targets range from $25.00 to $37.00.
Is Pfizer a buy according to analysts?
The consensus rating is “Buy” (1 strong buy, 8 buy, 17 hold, 1 sell, 1 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Pfizer expected to earn?
Analysts expect EPS of $3.05 for the fiscal year ending December 31, 2026 and $2.95 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.